Rules of Tumor Cell Development and Their Application to Biomarkers for Ovarian Cancer

Monica R. Mclemore

Christine Miaskowski

Bradley E. Aouizerat

Lee-May Chen

Marylin Dodd

tumor cell, biologic markers
ONF 2008, 35(3), 403-409. DOI: 10.1188/08.ONF.403-409

Purpose/Objectives: To apply the Hanahan and Weinberg conceptual framework for tumor development to the specific biomarkers observed or expressed in ovarian cancer.

Data Sources: Data-based publications, topical reviews, and book chapters.

Data Synthesis: Articles specific to ovarian cancer were reviewed to examine whether the six rules from the Hanahan and Weinberg conceptual framework were applicable to biomarkers of ovarian cancer. This approach allows for the application of a general framework for the development of solid tumors to the development of ovarian cancer.

Conclusions: The six rules for tumor cell development outlined in the Hanahan and Weinberg conceptual framework are applicable to biomarkers expressed or observed in patients with ovarian cancer.

Implications for Nursing: Oncology nurses can enhance their clinical teaching by integrating this information into their practice. Nurses who conduct research on ovarian cancer can use this framework to guide the selection of biomarker(s) for these studies. Finally, nurse educators can use this framework when teaching students key concepts in the care of patients with cancer.

Jump to a section


    Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., & Walter, P. (2002). Molecular biology of the cell (4th ed.). New York: Garland Science.
    Alvarez-Secord, A., Sayer, R., Snyder, S. A., Broadwater, G., Rodriguez, G. C., Berchuck, A., et al. (2004). The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecologic Oncology, 94(1), 74-79.
    Auersperg, N., Ota, T., & Mitchelle, G. W. (2002). Early events in ovarian epithelial carcinogenesis: Progress and problems in experimental approaches. International Journal of Gynecologic Cancer, 12(6), 691-703.
    Aunoble, B., Sanches, R., Didier, E., & Bignon, Y. J. (2000). Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. International Journal of Oncology, 16(3), 567-576.
    Candido Dos Reis, F. J., Moreira de Andrade, J., & Bighetti, S. (2002). CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. Gynecologic and Obstetric Investigation, 54(3), 132-136.
    Chin, D., Boyle, G. M., Parsons, P. G., & Coman, W. B. (2004). What is transforming growth factor-beta (TGF-beta)? British Journal of Plastic Surgery, 57(3), 215-221.
    Cirisano, F. D., & Karlan, B. Y. (1996). The role of the HER-2/neu oncogene in gynecologic cancers. Journal of the Society for Gynecologic Investigation, 3(3), 99-105.
    Counter, C. M., Hirte, H. W., Bacchetti, S., & Harley, C. B. (1994). Telomerase activity in human ovarian carcinoma. Proceedings of the National Academy of Sciences, 91(8), 2900-2904.
    Evan, G., & Littlewood, T. (1998). A matter of life and cell death. Science, 281(5381), 1317-1322.
    Faleiro-Rodrigues, C., Macedo-Pinto, I., Pereira, D., Ferreira, V. M., & Lopes, C. S. (2004). Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Human Pathology, 35(6), 663-669.
    Fraser, M., Leung, B., Jahani-Asl, A., Yan, X., Thompson, W. E., & Tsang, B. K. (2003). Chemoresistance in human ovarian cancer: The role of apoptotic regulators. Reproductive Biology and Endocrinology, 1, 66.
    Fujita, M., Enomoto, T., & Murata, Y. (2003). Genetic alterations in ovarian carcinoma: With specific reference to histological subtypes. Molecular and Cellular Endocrinology, 202(1-2), 97-99.
    Hahn, W. C., & Weinberg, R. A. (2002). Rules for making human tumor cells. New England Journal of Medicine, 347(20), 1593-1603.
    Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57-70.
    Hazelton, D., Nicosia, R. F., & Nicosia, S. V. (1999). Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clinical Cancer Research, 5(4), 823-829.
    Hsieh, C. Y., Chen, C. A., Chou, C. H., Lai, K. P., Jeng, Y. M., Kuo, M. L., et al. (2004). Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa/B: Implications for malignant ascites formation and tumor lymphangiogenesis. Journal of Biomedical Science, 11(2), 249-259.
    Jacobs, I., & Bast, R. C., Jr. (1989). The CA 125 tumour-associated antigen: A review of the literature. Human Reproduction, 4(1), 1-12.
    Kabawat, S. E., Bast, R. C., Welch, W. R., Knapp, R. C., & Colvin, R. B. (1983). Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types. American Journal of Clinical Pathologists, 79(1), 98-104.
    Kafali, H., Artunc, H., & Erdem, M. (2007). Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle. Archives of Gynecology and Obstetrics, 275(3), 175-177.
    Kan, Y. Y., Yeh, S. H., Ng, H. T., & Lou, C. M. (1992). Effect of menstruation on serum CA125 levels. Asia Oceania Journal of Obstetrics and Gynaecology, 18(4), 339-343.
    Kenemans, P., van Kamp, G. J., Oehr, P., & Verstraeten, R. A. (1993). Heterologous double-determinant immunoradiometric assay CA 125 II: Reliable second-generation immunoassay for determining CA125 in serum. Clinical Chemistry, 39(12), 2509-2513.
    King, R. C., & Stansfield, W. D. (2002). A dictionary of genetics. New York: Oxford University Press.
    Kui Wong, N., Easton, R. L., Panico, M., Sutton-Smith, M., Morrison, J. C., Lattanzio, F. A., et al. (2003). Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. Journal of Biological Chemistry, 278(31), 28619-28634.
    Matias-Guiu, X., & Prat, J. (1998). Molecular pathology of ovarian carcinomas. Virchows Archiv, 433(2), 103-111.
    Meden, H., & Kuhn, W. (1997). Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: A new prognostic factor. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 71(2), 173-179.
    Meden, H., Marx, D., Fattahi, A., Rath, W., Kron, M., Wuttke, W., et al. (1994). Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. Journal of Cancer Research and Clinical Oncology, 120(6), 378-381.
    Mukhopadhyay, D., & Datta, K. (2004). Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Seminars in Cancer Biology, 14(2), 123-130.
    Nussbaum, R. L., McInnes, R. R., Willard, H. F. (Eds.). (2001). Thompson and Thompson genetics in medicine (6th ed.). Philadelphia: Saunders.
    Nustad, K., Onsrud, M., Jannson, B., & Warren, D. (1998). CA125-epitopes and molecular size. International Journal of Biological Markers, 13(4), 196-199.
    Ribatti, D. (2005). The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: A historical review. British Journal of Haematology, 128(3), 303-309.
    Robertson, D. M., Pruysers, E., Burger, H. G., Jobling, T., McNeilage, J., & Healy, D. (2004). Inhibins and ovarian cancer. Molecular and Cellular Endocrinology, 225(1-2), 65-71.
    Roskelley, C. D., & Bissell, M. J. (2002). The dominance of the microenvironment in breast and ovarian cancer. Seminars in Cancer Biology, 12(2), 97-104.
    Rubin, S. C., & Sutton, G. P. (2004). Ovarian cancer (2nd ed.). Philadelphia: Lippincott Williams and Wilkins.
    Seelenmeyer, C., Wegehingel, S., Lechner, J., & Nickel, W. (2003). The cancer antigen CA125 represents a novel counter receptor for galectin-1. Journal of Cell Science, 116(Pt. 7), 1305-1318.
    Shayesteh, L., Lu, Y., Kuo, W. L., Baldocchi, R., Godfrey, T., Collins, C., et al. (1999). PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics, 21(1), 99-102.
    Sonmezer, M., Gungor, M., Ensari, A., & Ortac, F. (2004). Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: In association with transforming growth factor beta and vascular endothelial growth factor. International Journal of Gynecological Cancer, 14(1), 82-88.
    Sorak, M., Arsenijevic, S., Lukic, G., Arsenijevic, N., Ristic, P., Pavlovic, S., et al. (2007). Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma. Journal of the Balkan Union of Oncology, 12(1), 99-104.
    Sun, P. M., Wei, L. H., Luo, M. Y., Liu, G., Wang, J. L., & Mustea, A. (2007). The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 130, 249-257.
    Sundfeldt, K. (2003). Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Molecular and Cellular Endocrinology, 202(1-2), 89-96.
    Tammela, T., Enholm, B., Alitalo, K., & Paavonen, K. (2005).The biology of vascular endothelial growth factors. Cardiovascular Research, 65(3), 550-563.
    Tannock, I. F., Hill, R. P., Bristow, R. G., & Harrington, L. (2005). The basic science of oncology (4th ed.). San Francisco: McGraw-Hill.
    Tong, S., Wallace, E. M., & Burger, H. G. (2003). Inhibins and activins: Clinical advances in reproductive medicine. Clinical Endocrinology, 58(2), 115-127.
    Verheijen, R. H., von Mensdorff-Pouilly, S., van Kamp, G. J., & Kenemans, P. (1999). CA 125: Fundamental and clinical aspects. Seminars in Cancer Biology, 9(2), 117-124.
    Villa, R., Folini, M., Perego, P., Supino, R., Setti, E., Daidone, M. G., et al. (2000). Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: Correlation with sensitivity to DNA damaging agents. International Journal of Oncology, 16(5), 995-1002.
    Wenham, R. M., Lancaster, J. M., & Berchuck, A. (2002). Molecular aspects of ovarian cancer. Best Practice and Research. Clinical Obstetrics and Gynaecology, 16(4), 483-497.
    Zhang, L., Yang, N., Katsaros, D., Huang, W., Park, J. W., Fracchioli, S., et al. (2003). The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Research, 63(14), 4225-4231.